Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 Fucà, 2018, Immunotherapy-based combinations: an update, Curr Opin Oncol, 30, 345, 10.1097/CCO.0000000000000466 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced Nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Aguiar, 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data, Immunotherapy, 9, 499, 10.2217/imt-2016-0150 Rizvi, 2015, Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 48, 124, 10.1126/science.aaa1348 Putzu, 2018, Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with nivolumab, Cancer Immunol Immunother, 67, 1349, 10.1007/s00262-018-2182-4 Zer, 2018, Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer, Clin Lung Cancer, 19, 426, 10.1016/j.cllc.2018.04.008 Park, 2018, Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab, Clin Lung Cancer, 19, 280, 10.1016/j.cllc.2017.12.007 Diem, 2017, Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab, Lung Cancer, 111, 176, 10.1016/j.lungcan.2017.07.024 Suh, 2018, Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody, Cancer Immunol Immunother, 67, 459, 10.1007/s00262-017-2092-x Bagley, 2017, Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer, 106, 1, 10.1016/j.lungcan.2017.01.013 Shi, 2018, Cancer immunotherapy: a focus on the regulation of immune checkpoints, IJMS, 19, 1389, 10.3390/ijms19051389 Fucà, 2018, Low baseline serum sodium concentration is associated with poor clinical outcomes in metastatic non-small cell lung cancer patients treated with immunotherapy, Target Oncol, 13, 795, 10.1007/s11523-018-0599-5 Remon, 2018, Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions, Cancer Treat Rev, 64, 21, 10.1016/j.ctrv.2018.02.002 Leonardi, 2018, Safety of programmed Death–1 pathway inhibitors among patients with Non–Small-Cell lung cancer and preexisting autoimmune disorders, JCO, 36, 1905, 10.1200/JCO.2017.77.0305 Martinez-Bernal, 2017, Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients, Ann Oncol, 28:1323P Arbour, 2018, Impact of baseline steroids on efficacy of programmed cell death-1 and programmed Death-Ligand 1 blockade in patients with Non–Small-Cell lung cancer, JCO, 36, 2872, 10.1200/JCO.2018.79.0006 Leighl, 2015, Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use, J Thorac Oncol, 10, S66 Coutinho, 2011, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, Mol Cell Endocrinol, 335, 2, 10.1016/j.mce.2010.04.005 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), European Journal of Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Mezquita, 2018, Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer, JAMA Oncol, 4, 351, 10.1001/jamaoncol.2017.4771 Heppt, 2017, Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition, Eur J Cancer, 82, 56, 10.1016/j.ejca.2017.05.038 Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, 22, 5487, 10.1158/1078-0432.CCR-16-0127 Russo, 2018, Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel, J Cell Physiol, 233, 6337, 10.1002/jcp.26609 Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X SCScott, NAPennell. Brief report: early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. Dumenil, 2018, Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab, PLoS One, 13, 10.1371/journal.pone.0195945 Herold, 2006, Glucocorticoids in T cell apoptosis and function, Cell. Mol. Life Sci., 63, 60, 10.1007/s00018-005-5390-y Colotta, 1993, Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4, Science, 261, 472, 10.1126/science.8332913 Tetel, 2018, Steroids, stress and the gut microbiome-brain axis, J Neuroendocrinol, 30, e12548, 10.1111/jne.12548 Libert, 2014, How steroids steer T cells, Cell Rep, 7, 938, 10.1016/j.celrep.2014.04.041 Franchimont, 1998, Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures, Regul Pept, 73, 59, 10.1016/S0167-0115(97)01063-X Edward, 2017, Selective expansion of human regulatory T cells in nasal polyps, and not adjacent tissue microenvironments, in individual patients exposed to steroids, Clin Immunol, 179, 66, 10.1016/j.clim.2017.02.002 Sica, 2012, Macrophage plasticity and polarization: in vivo veritas, J. Clin. Invest., 122, 787, 10.1172/JCI59643 Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 Shore, 2015, Advances in the understanding of cancer immunotherapy, BJU Int, 116, 321, 10.1111/bju.12692 Chen, 2016, Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, Cancer Discov, 6, 827, 10.1158/2159-8290.CD-15-1545 Lanza, 1996, Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes, Clin Exp Immunol, 103, 482, 10.1111/j.1365-2249.1996.tb08306.x Haratani, 2018, Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer, JAMA Oncol, 4, 374, 10.1001/jamaoncol.2017.2925 Fujii, 2018, Incidence of immune-related adverse events and its association with treatment outcomes: the MD anderson cancer center experience, Invest New Drugs, 36, 638, 10.1007/s10637-017-0534-0 Mehra, 2017, Neutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroids, Clin Genitourin Cancer, 15, 678, 10.1016/j.clgc.2017.05.012 Hajkova, 2017, Mesenchymal stem cells attenuate the adverse effects of immunosuppressive drugs on distinct T cell Subopulations, Stem Cell Rev and Rep, 13, 104, 10.1007/s12015-016-9703-3 Akbay, 2017, Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade, J Thorac Oncol, 12, 1268, 10.1016/j.jtho.2017.04.017 Meagher, 1996, Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes, J Immunol, 156, 4422, 10.4049/jimmunol.156.11.4422